Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia

GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?

Predicting early relapse in transplant-eligible MM patients using baseline prognostic features and MRD negativity

Using multiparameter flow cytometry and next generation sequencing to evaluate MRD in NDMM patients from the FORTE trial

Complete remission after induction chemotherapy determines clinical efficacy of relapse-preventive immunotherapy in AML

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM

Myeloma highlights from ASH 2019

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results

FLT3-inhibition in infants with acute lymphoblastic leukaemia

Chronic lymphocytic leukaemia highlights from ASH 2019

Benefits of apixaban among venous thromboembolism patients with active cancer

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-negative ALL